Nov 1, 2018
FDA Puts the Kibosh on Canakinumab for Cardiac Indication—at Least for Now
FDA Puts the Kibosh on Canakinumab for Cardiac Indication—at Least for Now
What’s next for canakinumab? Novartis says they’re still mulling a complete response letter they received in response to its bid for a new CVD indication.
The US Food and Drug Administration (FDA) has thrown a wrench into Novartis’s plans for the treatment of inflammation to prevent cardiovascular disease. Earlier this month, the company announced they’d received a complete response letter…
View On WordPress